Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study to Evaluate Safety, Tolerability, and Immunogenicity of a Prophylactic Plasmid DNA Vaccine Against SARS-CoV-2 [Covigenix VAX-001/VAX-001-1b] in Healthy Adults 18 Years and Older

NCT04591184 is registered in ClinicalTrials.gov with Entos Pharmaceuticals Inc. as lead sponsor.

NCT NCT04591184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04591184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study to Evaluate Safety, Tolerability, and Immunogenicity of a Prophylactic Plasmid DNA Vaccine Against SARS-CoV-2 [Covigenix VAX-001/VAX-001-1b] in Healthy Adults 18 Years and Older
Lead sponsor
Entos Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 7, 2021
Completion date
December 6, 2023
Enrollment
268 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2